The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
about
Management of patients with biochemical recurrence after local therapy for prostate cancerHuman prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadeChanges in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancerThe prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?The utility of prostate-specific antigen in the management of advanced prostate cancer.Intermittent androgen deprivation therapy in advanced prostate cancer.Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?Management Options for Biochemically Recurrent Prostate Cancer.First off-time treatment prostate-specific antigen kinetics predicts survival in intermittent androgen deprivation for prostate cancer.Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level.Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.
P2860
Q26849220-07B65AAA-F92D-4F62-B28F-985A9068DD9CQ34645401-7331182F-A8CC-401E-A1D8-BCCA8065BE3AQ35776240-BAB1A976-6BEF-4CC1-A8D5-D5DB2553D702Q37074125-16A587C0-914E-4EA4-8C40-CDAD08C20262Q38119260-320BF793-B060-4337-9D58-46447E8F3C65Q38176254-A21D8F2E-9E5E-4FE3-B839-DA0499094475Q38179060-11E382CE-1117-4D6A-8DCF-F14D303F95E6Q38691937-B086E87A-7264-47C4-BEE5-8F5EDC20B30CQ41188480-85CCC0FE-661D-434A-8E7B-270D89EF19BFQ44884425-45132E54-F0A6-4218-A7B7-BEB3328B2A41Q45377392-3FC5902B-15DD-46BA-8779-A5C14D80443CQ55262610-96209E74-4241-4218-96D7-491901BF202A
P2860
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The change of PSA doubling tim ...... rmittent androgen deprivation.
@en
type
label
The change of PSA doubling tim ...... rmittent androgen deprivation.
@en
prefLabel
The change of PSA doubling tim ...... rmittent androgen deprivation.
@en
P2093
P2860
P356
P1433
P1476
The change of PSA doubling tim ...... ermittent androgen deprivation
@en
P2093
Daniel Keizman
Janet Walczak
Jenny J Kim
Mario A Eisenberger
Michael A Carducci
Peng Huang
Samuel Denmeade
Victoria Sinibaldi
P2860
P304
P356
10.1002/PROS.21377
P577
2011-03-22T00:00:00Z